Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill directs the Department of Health and Human Services (HHS) to expand, coordinate, and support research on uterine fibroids through the National Institutes of Health and other agencies, and authorizes $30 million annually for research for fiscal years 2026–2030. It requires HHS to establish or expand a Medicaid/CHIP research database on services for individuals with uterine fibroids and to report to Congress within two years on Federal and State spending for such services.
Adequacy and fiscal bounds of funding: liberals view $30M/year as helpful but limited; conservatives worry about open-ended authorizations for education/outreach.
Relative to its intended legislative type, this bill establishes new substantive federal authorities and funding for uterine fibroid research and requires data collection and reporting and public and provider education.
This bill directs the Department of Health and Human Services (HHS) to expand, coordinate, and support research on uterine fibroids through the National Institutes of Health and other agencies, and authorizes $30 million annually for research for fiscal years 2026–2030.
It requires HHS to establish or expand a Medicaid/CHIP research database on services for individuals with uterine fibroids and to report to Congress within two years on Federal and State spending for such services.
The bill directs HHS to run a public education program about uterine fibroids — including prevalence, elevated risk among minority individuals, and non-hysterectomy treatment options — and to disseminate evidence-based information to health care providers in consultation with medical societies.
On content alone, this is a narrowly scoped, technocratic bill addressing a common medical condition with documented disparities and modest authorized funding — characteristics that tend to attract bipartisan support. Main barriers are legislative calendar and the separate appropriations process (authorization vs. actual funding), plus routine committee and floor procedure in each chamber. Because it does not create controversial mandates or preempt state authority, its content does not present major ideological obstacles, but passage still depends on congressional priorities and competing budgetary demands.
Relative to its intended legislative type, this bill establishes new substantive federal authorities and funding for uterine fibroid research and requires data collection and reporting and public and provider education. It defines the problem clearly and ties proposed actions to existing statutory authorities, but leaves significant implementation details, data safeguards, funding specificity for non-research activities, and performance accountability under-specified.
Adequacy and fiscal bounds of funding: liberals view $30M/year as helpful but limited; conservatives worry about open-ended authorizations for education/outreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Adequacy and fiscal bounds of funding: liberals view $30M/year as helpful but limited; conservatives worry about open-ended authorizations for education/outreach.
A mainstream liberal would likely view the bill favorably as a targeted federal response to a widespread but under-researched women’s health issue that disproportionately affects people of color.
They would appreciate the explicit focus on disparities, the NIH coordination, and dedicated research funding that could yield fertility-friendly treatments and reduce reliance on hysterectomy.
They might press for robust community outreach, culturally competent education, and stronger commitments to ensure equitable access to any new treatments.
A moderate would probably view the bill as a pragmatic, narrowly targeted health-research and education measure that addresses clear gaps in knowledge and disparities without dramatic regulatory change.
They would welcome the explicit appropriation for NIH research and the data/reporting requirements that could improve evidence for cost-effective care.
They would want clearer metrics, cost controls, and assurance the programs avoid duplication with existing federal initiatives.
A mainstream conservative would approach the bill with skepticism about expanding federal programs and spending, but might not oppose studying and improving care for a common health condition.
Concerns would center on new federal data collection burdens on states, open-ended spending authorizations, and further growth of federal involvement in medical practice.
They may accept a narrowly tailored research appropriation but want stricter fiscal limits, state flexibility, and assurance the program does not mandate clinical practice changes or overstep private-sector roles.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, this is a narrowly scoped, technocratic bill addressing a common medical condition with documented disparities and modest authorized funding — characteristics that tend to attract bipartisan support. Main barriers are legislative calendar and the separate appropriations process (authorization vs. actual funding), plus routine committee and floor procedure in each chamber. Because it does not create controversial mandates or preempt state authority, its content does not present major ideological obstacles, but passage still depends on congressional priorities and competing budgetary demands.
The bill has not accumulated any surfaced votes yet.
Adequacy and fiscal bounds of funding: liberals view $30M/year as helpful but limited; conservatives worry about open-ended authorizations…
On content alone, this is a narrowly scoped, technocratic bill addressing a common medical condition with documented disparities and modest…
Relative to its intended legislative type, this bill establishes new substantive federal authorities and funding for uterine fibroid research and requires data collection and reporting and public and provider education.…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.